In Australia in the last five years, an estimated 6066 women per year have undergone hysterectomies to treat fibroid-related diseases, while just 145 women each year have undergone a uterine artery embolisation, or UAE.
The procedure can effectively treat the majority of bleeding uterine fibroids. Each year, thousands of Australian women undergo invasive and life-altering hysterectomies to treat debilitating pain and blood loss caused by uterine fibroids. But there’s another option: a minimally invasive, pin-hole procedure that treats the symptoms, yet leaves the uterus intact.
Professor Warren Clements, interventional radiologist and head of the UAE service at The Alfred, said despite the proven safety and efficacy of the procedure – which was developed in the 1990s – it is simply not provided as an option to many women, something he urgently wants to change.
“Fibroids are highly prevalent in society and women need access to a range of different treatments so that they can choose what is the best for them,” Prof Clements said in an interview with Australian Health Journal.
“Every year, many women have a hysterectomy who would be suitable for a non-surgical alternative. UAE is an amazing non-surgical treatment and allows women to keep their uterus if they want to.”
The procedure is all done through a single pinhole incision, whereas a hysterectomy requires open surgery. It involves using low-dose x-rays and contrast dye to guide catheters through the arteries towards fibroids in the uterus. A medication is used to block the blood supply to the fibroids, which causes them to shrink. The procedure takes about half an hour, is done under ‘twilight’ sedation, and only requires one overnight recovery stay.
”Many women aren’t aware that this is a very minor procedure compared to hysterectomy,” Prof Clements said. “Women can resume normal activities the following day. The recovery is short, and most women can go back to work within a week. More than 90 per cent of women with heavy periods will have significant improvement in their symptoms after UAE.”
Professor Warren Clements, is also Honorary Researcher – Interventional Radiology, National Trauma Research Institute, Professor, Interventional Radiologist (IR) and the Head of Fluoroscopy in the Department of Radiology at Alfred Health. He is also a Fellow of the Royal Australian and New Zealand College of Radiologists (RANZCR).
Credit: Alfred Health
You Might also like
-
Australian Healthcare and Hospitals Association Hospitals and Clinics Innovation New Content Robotics Technology
Future of minimally invasive surgery
Macquarie University Hospital is the first hospital in Australia to have three robotic surgical systems. It remains the busiest centre for robotic urology in New South Wales and has rapidly growing programs in other areas. What is behind the Hospital’s success?
Conjoint Associate Professor Walter Kmet, CEO of Macquarie University Hospital, says that the story of robotics at the Hospital is driven by its academic health sciences identity.
-
Generosity of spirit in teaching
The Ramaciotti Medal for Excellence is considered one of the most prestigious awards in biomedical research in Australia and is highly sought after by researchers in the field.
In 2022, Professor Matthew Kiernan was the recipient of the Ramaciotti Medal for Excellence and the associated $50,000 award.
Australian Health Journal spoke with Professor Kiernan to hear about his journey in medicine and science to try and uncover and understand diseases and his generosity of spirit to pass on what he has learnt.
-
Improved treatment in advanced-stage Hodgkin lymphoma
A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen.
Australian Health Journal spoke with Professor Mark Hertzberg in his role in the ALLG HD10 Clinical Trial and as a former Chair of the Scientific Advisory Committee of the Australasian Leukaemia & Lymphoma Group (ALLG), an organisation involved in improving the treatments and lives of blood cancer patients.